{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-088234","form_type":"8-K","ticker":"AMRN","cik":"0000897448","company_name":"AMARIN CORP PLCUK","filed_at":"2024-07-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:16.234577+00:00","generated_at":"2026-05-31T14:43:29.366243+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Amarin Q2 revenue down 16% to $67.5M; PBM drops VASCEPA coverage; new CEO","bullets":["Total net revenue $67.5M (-16% YoY); net product revenue $47.5M (-27%) pressured by US generic competition.","GAAP net income $1.5M (EPS $0.00) vs net loss $17.6M in Q2 2023; non-GAAP adj. net income $5.9M.","Cash $306.7M; $50M share repurchase program approved but not commenced.","Large PBM removed VASCEPA from exclusive coverage for Commercial national formularies effective July 1, 2024.","CEO Aaron Berg appointed; China CVRR milestone $15M; new EU patent extending VAZKEPA exclusivity to 2039."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-088234","json":"https://secwatch.observer/filing/0000950170-24-088234.json","markdown":"https://secwatch.observer/filing/0000950170-24-088234.md","text":"https://secwatch.observer/filing/0000950170-24-088234.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/897448/000095017024088234/0000950170-24-088234-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/897448/000095017024088234/amrn-20240731.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T14:43:29.366243+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}